High-resolution computed tomography shows evidence of ILD.
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!
Glucocorticoids are widely prescribed by rheumatologists, and the effects of daily and cumulative doses of these drugs on bone mineral density (BMD) are important elements of a draft clinical guideline document presented on Nov. 13 at the 2016 ACR/ARHP Annual Meeting in Washington, D.C. Leaders of the ACR guideline project discussed their recommendations at the…
As the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) is implemented in January with new models for quality-based reimbursement payments, rheumatologists must seize control of how they will be paid now—and in the future. This message was stressed by speakers during Holy MACRA! How to Survive and Thrive in the Era of MACRA,…
As he prepares to take on his newest volunteer role with the ACR, leading the Government Affairs Committee (GAC), Angus Worthing, MD, FACR, FACP, is looking forward to making the most of the opportunities that a unified government can offer the ACR in advocating for rheumatology care. “Advocacy is an investment in our profession—regardless of…
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…
This past June, Yvonne Golightly, PT, MS, PhD, helped launch an international group of researchers focused on foot and ankle osteoarthritis. At the time, Dr. Golightly, an assistant professor in the department of epidemiology at the University of North Carolina (UNC), Chapel Hill, N.C., was attending the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR)…
On Nov. 12, nearly 150 supporters of the Rheumatology Research Foundation gathered at the St. Regis Washington, D.C., for the Donors of Merit recognition dinner. This annual event honors those who contributed to the Foundation throughout the year. Foundation President Eric Matteson, MD, MPH, applauded leaders who have played an essential role in the Foundation’s success….
WASHINGTON (Reuters)—U.S. Senate Majority Leader Mitch McConnell (R-Ky.) says the Senate will move to repeal President Barack Obama’s healthcare law shortly after Jan. 1, but declined to give a timeline for a plan to replace it. McConnell says the Senate would vote as soon as it returns from its year-end recess to repeal Obamacare. “And…
(Reuters)—Dr. Scott Gottlieb, a partner at one of the world’s largest venture capital funds and a former deputy commissioner at the U.S. Food and Drug Administration, is being considered by President-Elect Donald Trump to run the agency, according to sources close to the transition team. Gottlieb, 44, a venture partner at New Enterprise Associates and…
NEW YORK (Reuters)—The largest lobbying group for health insurers has asked U.S. lawmakers weighing the fate of Obamacare to push back the due date for 2018 individual insurance submissions to regulators in hopes of obtaining greater clarity on the program’s future later on. Republican leaders including President-elect Donald Trump and U.S. Senate Majority Leader Mitch…
It’s an honor and a thrill to be the next chair of the Government Affairs Committee. Boy, do we have a big year ahead.